First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
Status:
Recruiting
Trial end date:
2027-09-15
Target enrollment:
Participant gender:
Summary
The goal of this prospective, phase IV, multi-centre clinical trial is to to define the
proportion of patients with advanced high grade epithelial ovarian cancer (EOC) HRD-positive
who will be treated at first line with olaparib in combination with bevacizumab as
maintenance and to describe their clinical and demographic characteristics. Other primary
objective is to confirm, in a setting close to clinical practice, the efficacy of olaparib
concomitant with bevacizumab as maintenance treatment after first-line chemotherapy in
patients with advanced high grade EOC HRD-positive and who have received bevacizumab in
combination with chemotherapy.
Phase:
Phase 4
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research